Inhalable compositions for use in the treatment of pulmonary diseases

A method of delaying the onset of bronchiolitis obliterans in a subject, the method comprising administering a pharmaceutical composition comprising cyclosporine A in liposomally solubilized form to the subject after lung transplantation,

• wherein the pharmaceutical composition is administered to the subject by inhalation in the form of an aerosol, and
• wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer, the nebulizer comprising:
• a) an aerosol generator comprising:
• a fluid reservoir for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and
• a vibratable membrane having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter of up to about 4.0 μm as measured with a 0.9% (w/v) aqueous solution of sodium chloride;
• b) a chamber for temporarily accommodating the aerosol generated by the aerosol generator, the chamber having an inner lumen with a volume in the range of from about 50 to about 150 ml;
• and
• c) a mouthpiece for delivering the aerosol supplied by the nebulizer to the subject, the mouthpiece having an exhalation filter;
• wherein the mouthpiece comprises:
• a body defining a fluid path from an inlet port connectable to the nebulizer to an inhalation opening to be received in the mouth of the subject;
• and
• an exhalation filter having a filter base in fluid communication with the fluid path, a filter top detachably connected to the filter base and a filter material provided between the filter base and the filter top, wherein the filter top has an exhalation opening cooperating with a one-way valve allowing exhaustion of fluid from the fluid path through the filter material to the outside of the mouthpiece upon exhalation of a patient through the inhalation opening;
• wherein the body and the filter base are an integrated one-piece unit.